Medicine Access Programmes: what do patients think - a patient-reported outcome study on ribociclib in metastatic breast cancer in Australia

Author(s): Yap, N; Wong, V; Morton, C; De Boer, R; Baron-Hay, S; Blum, R; Forster, B; Chua, S; Clarke, K; Cuff, K; Green, M; Lim, E; Mok, K; Nott, L; Nottage, M; Tafreshi, A; Tsoi, D; Uccellini, A; Gibbs, P; Lok, SW;
Details: Publication Year 2024-11,Volume 54,Issue #11,Page 1894-1897
Journal Title: Internal Medicine Journal
Abstract: This study evaluated patient-reported outcomes (PROs) of Medicine Access Programmes (MAPs) for Australian metastatic breast cancer patients on ribociclib. Limited patient awareness of MAP enrolment was identified, emphasising the need for improved education and consent processes. Most patients expressed gratitude for accessing non-funded medications and perceived enhanced medication adherence as a key benefit. Integrating PRO data with real-world registry data provides comprehensive insight for future MAP development.
Publisher: Wiley
Keywords: Humans; *Breast Neoplasms/drug therapy/pathology; Female; Australia; *Patient Reported Outcome Measures; Middle Aged; *Purines/therapeutic use; *Aminopyridines/therapeutic use; Aged; Adult; Medication Adherence; Health Services Accessibility; Antineoplastic Agents/therapeutic use; Neoplasm Metastasis; Medication Access Programme; patient-reported outcome; quality of life
Research Division(s): Personalised Oncology
PubMed ID: 39467087
Publisher's Version: https://doi.org/10.1111/imj.16536
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-12-05 11:13:29

Last Modified: 2024-12-05 11:14:13